Transfusion of red blood cells: the impact on short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-up. by van Straten, Albert et al.
DOI: 10.1510/icvts.2009.214551 
2009; 
 2010;10:37-42; originally published online Oct 8,Interact CardioVasc Thorac Surg
Wolf 
A.J. van Zundert, Elisabeth J. Martens, Jacques P.A.M. Schönberger and Andre M. de 
Albert H.M. van Straten, Margreet W.A. Bekker, Mohamed A. Soliman Hamad, André
 after coronary artery bypass grafting, a ten-year follow-up
Transfusion of red blood cells: the impact on short-term and long-term survival
 http://icvts.ctsnetjournals.org/cgi/content/full/10/1/37
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
1569-9293. 
(ESCVS). Copyright © 2010 by European Association for Cardio-thoracic Surgery. Print ISSN:
for Cardio-thoracic Surgery (EACTS) and the European Society for Cardiovascular Surgery 
 is the official journal of the European AssociationInteractive Cardiovascular and Thoracic Surgery
 by on February 23, 2010 icvts.ctsnetjournals.orgDownloaded from 
ARTICLE IN PRESS
www.icvts.org
doi:10.1510/icvts.2009.214551
Interactive CardioVascular and Thoracic Surgery 10 (2010) 37–42
 2010 Published by European Association for Cardio-Thoracic Surgery
N
ew
Ideas
Institutional
Report
W
ork
in
Progress
Report
ESCVS
Article
N
egative
Results
State-of-the-art
Best
Evidence
Topic
Brief
Com
m
unication
Case
Report
Follow
-up
Paper
Editorial
Protocol
Proposalfor
Bail-
out
Procedure
N
om
enclature
H
istorical
Pages
Institutional report - Coronary
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long-term survival after coronary artery bypass grafting,
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Abstract
Transfusion of red blood cells (RBC) and other blood products in patients undergoing coronary artery bypass grafting (CABG) is associated
with increased mortality and morbidity. We retrospectively analyzed data of patients who underwent an isolated coronary bypass graft
operation between January 1998 and December 2007. Mean follow-up was 1696"1026 days, with exclusion of 122 patients lost to follow-
up and 80 patients who received 10 units of RBC. Of the remaining patients, 8001 (76.7%) received no RBC, 1621 (15.2%) received 1–2
units of RBC, 593 (5.7%) received 3–5 units and 220 (2.1%) received 6–10 units. The number of transfused RBC was a predictor for early
but not for late mortality. When compared to expected survival, survival of patients not receiving any blood product was better, while
survival of patients receiving )3 units of RBC was worse. Transfusion of RBC is an independent, dose-dependent risk factor for early
mortality after revascularization. Compared to expected survival, receiving no RBC improves patient long-term survival, whereas receiving
three or more units of RBC significantly decreases patient survival.
 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
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1. Introduction
Transfusion of red blood cells (RBC) in patients undergoing
coronary artery bypass grafting (CABG) is associated with
increased mortality and morbidity w1–4x. Transfusion of RBC
as a risk factor for early mortality has been well established
whereas the effect of RBC transfusion on late mortality has
been less well described.
This study analyzes the effect of perioperative transfusion
of RBC on short- and long-term mortality after CABG in our
centre and compares survival rates with expected survival
based on the general Dutch population.
2. Methods
The study was performed after permission of the local
Medical Ethics Committee. We studied the data of all
patients undergoing isolated CABG in our center between
January 1998 and December 2007. Clinical data were pro-
spectively collected in our database. Patients were classi-
fied into four groups stratified by number of units of
transfused RBC: group 1 did not receive any unit of RBC;
*Corresponding author. Tel.: q31 40 239 86 80; fax: q31 40 244 02 68.
E-mail address: aasmsn@cze.nl (M.A. Soliman Hamad).
ns6828 (65.5%), group 2 received 1–2 units; ns2371
(22.7%), group 3 received 3–5 units; ns900 (8.6%) and
group 4 received 6–10 units; ns326 (3.1%). Patients with
)10 units of transfused RBC were excluded from further
analyses (ns69).
Normothermic extra-corporeal circulation (ECC) was per-
formed using non-pulsatile flow. Cold crystalloid cardiople-
gia (‘St Thomas’ solution) or warm blood cardioplegia was
used to induce and maintain cardioplegic arrest, according
to the surgeon’s preference. All patients undergoing CABG
with the use of ECC, received a low dose aprotinin (2
million kallikrein inactivating units) during ECC.
Follow-up data concerning mortality of patients were
gathered using databases of health insurance companies,
general practitioners and local authorities. Early mortality
was defined as any cause mortality F30 days postopera-
tively, while late mortality was defined as any cause
mortality )30 days.
To calculate the survival rate of general population
cohorts that were matched for age and gender with patient
groups, data were used from the database of the Dutch
Central Bureau for Statistics (CBS). We considered the
survival of the matched population cohort the expected
survival of the patient group.
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Table 1
Baseline characteristics stratified by received units of red blood cells
0 RBC 1–2 RBC 3–5 RBC 6–10 RBC P-value
ns6828 ns2371 ns900 ns326
Age 63.2"9.4 67.1"9.2 67.7"9.5 67.4"9.3 -0.0001
Male 5934 (86.9) 1387 (58.5) 485 (53.9) 219 (67.2) -0.0001
Diabetes 1370 (20.1) 554 (23.4) 207 (23.0) 65 (19.9) 0.003
Hypertension 2799 (41.0) 1016 (42.9) 394 (43.8) 142 (43.6) 0.191
COPD 830 (12.2) 291 (12.3) 137 (15.2) 51 (15.6) 0.020
PVD 723 (10.6) 324 (13.7) 111 (12.3) 51 (15.6) -0.0001
EF-35% 188 (2.8) 97 (4.2) 43 (5.0) 20 (6.8) -0.0001
CrCl mlØmin-1 79.2"25.5 63.4"22.4 60.2"24.1 59.5"25.4 -0.0001
Preoperative Hb gØdl-1 14.3"1.1 13.2"1.3 12.8"1.5 13.0"1.7 -0.0001
Emergency 136 (2.0) 104 (4.4) 100 (11.1) 77 (23.6) -0.0001
Off-pump 774 (11.3) 110 (4.6) 33 (3.7) 11 (3.4) -0.0001
Duration of ECC 54.1"33.8 61.9"30.1 66.2"33.9 74.0"43.1 -0.0001
Redo 279 (4.1) 150 (6.3) 126 (14.0) 64 (19.6) -0.0001
Number of grafts 3.4"1.1 3.5"1.0 3.3"1.1 3.4"1.1 0.002
Number of FFP 0.03"0.26 0.19"0.68 0.58"1.14 2.47"2.32 -0.0001
Number of platelets 0.01"0.01 0.02"0.02 0.09"0.36 0.45"0.82 -0.0001
Results as number (percentage) or mean"S.D. COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; EF, ejection fraction; Preop
CrCl, preoperative creatinine clearance; Hb, hemoglobin level; ECC, extra-corporeal circulation; Redo, previous cardiac surgery; FFP, fresh frozen plasma; RBC,
red blood cells.
Table 2
Postoperative complications stratified by received units of red blood cells
Complication 0 RBC 1–2 RBC 3–5 RBC 6–10 RBC P-value
ns6828 ns2371 ns900 ns326
Renal failure 5 (0.1) 18 (0.7) 16 (1.8) 15 (4.5) -0.0001
(need for dialysis)
CVA 37 (0.5) 24 (1.0) 15 (1.7) 8 (2.4) -0.0001
Mediastinitis 41 (0.6) 30 (1.2) 10 (1.1) 7 (2.1) -0.0001
IABP 43 (0.6) 46 (1.9) 70 (7.8) 55 (16.9) -0.0001
Re-exploration 97 (1.4) 105 (4.4) 159 (17.7) 166 (50.9) -0.0001
Periop MI 104 (1.5) 89 (3.8) 66 (7.3) 39 (12.0) -0.0001
Data are expressed as number (percentage). CVA, cerebrovascular acci-
dent; IABP, intra-aortic balloon pump support; Periop MI, perioperative myo-
cardial infarction; RBC, red blood cells.
2.1. Statistical analyses
Discrete variables were compared with the x -test and2
are presented as numbers and percentages. Continuous
variables were compared with the Student t-test and anal-
ysis of variance (ANOVA). Univariate and multivariate logis-
tic and Cox proportional hazard regression analyses were
performed to investigate the impact of perioperative trans-
fusion of blood products on early and late mortality at
follow-up. Univariate analyses were used to test for the
potentially confounding effect of biomedical and demo-
graphic factors on outcome. The cumulative long-term
survival was estimated according to the Kaplan–Meier
method, comparing differences between groups with the
log-rank test. One-, five- and ten-year survival were com-
pared using the time table method and the Wilcoxon test.
A P-0.05 was used for all tests to indicate statistical
significance. All statistical analyses were performed using
SPPS version 15.0 (SPSS Inc, Chicago, IL).
3. Results
During a ten-year period (January 1998 until December
2007) 10,626 patients underwent CABG. After excluding
patients who were lost to follow-up (ns122) and patients
who received )10 units of RBC (ns80), 10,425 patients
were analyzed. The total number of transfused units of
RBC was 10,006; the total number of transfused units of
fresh frozen plasma (FFP) was 2095; and the total number
of transfused units of platelets was 375. The minimum
follow-up period for surviving patients was 60 days. Mean
follow-up was 1691"1058 days wrange: 0 (operative
death)–3708 daysx. Median was 1629 days.
Baseline characteristics stratified by the number of
received units of RBC are shown in Table 1.
Patients in group 1 were more often younger males, had
less often chronic obstructive pulmonary disease (COPD)
and peripheral vascular disease (PVD), had a better left
ventricular function wejection fraction (EF) )35%x, renal
function and a higher preoperative hemoglobin level and a
shorter duration of ECC (ECC-time). Emergency operations
and previous cardiac surgery were seen more frequently in
groups 3 and 4. Patients receiving more RBC received also
more FFP and platelets.
The incidence of postoperative complications stratified by
the number of received units of RBC is shown in Table 2.
Univariate logistic regression analyses revealed the num-
bers of units of RBC, FFP and platelets as continuous
variables as risk factors for early mortality (Table 3).
All risk factors that were identified with univariate logistic
regression analyses were entered into a multivariate logis-
tic regression model. The number of units of RBC as a
continuous variable was an independent risk factor for
early mortality.
Results of Cox regression analyses regarding risk factors
of late mortality are shown in Table 4. Univariate analyses
revealed the numbers of units of transfused RBC, FFP and
platelets as risk factors for late mortality.
All risk factors that were identified with univariate anal-
yses were entered into the multivariate Cox regression
model. The number of units of transfused RBC, FFP and
platelets were not identified as predictors of late mortality.
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Table 3
Predictors of early mortality (F30 days post-CABG); univariate and multivariate logistic regression analyses
Risk factor Univariate analyses Multivariate analysis
early mortality early mortality
HR (95% CI) P-value HR P-value
RBC 1.308 (1.267–1.351) -0.0001 1.214 (1.126–1.308) -0.0001
FFP 1.397 (1.326–1.471) -0.0001 0.904 (0.783–1.043) 0.165
Platelets 2.806 (2.368–3.326) -0.0001 1.136 (0.764–1.688) 0.529
Agea 1.082 (1.065–1.099) -0.0001 1.060 (1.036–1.085) -0.0001
Male gender 0.77 (0.58–1.02) 0.068
COPD 1.91 (1.41–2.60) -0.0001 1.84 (1.27–2.65) 0.001
Diabetes 1.48 (1.12–1.96) 0.005 1.59 (1.14–2.23) 0.006
CrCl mlØmin-1a 0.971 (0.966–0.976) -0.0001 0.987 (0.979–0.995) 0.002
EF-35% 6.02 (4.17–8.68) -0.0001 4.56 (2.86–7.26) -0.0001
Preop Hba 0.696 (0.640–0.758) -0.0001 0.997 (0.894–1.113) 0.962
PVD 1.60 (1.16–2.23) 0.005 1.02 (0.67–1.55) 0.906
Redo 4.26 (3.12–5.84) -0.0001 1.32 (0.81–2.14) 0.259
Emergency 6.78 (4.94–9.31) -0.0001 1.20 (0.61–2.38) 0.590
Year of operation 0.947 (0.906–0.989) 0.014 1.006 (0.951–1.063) 0.840
ECC-timea 1.011 (1.007–1.014 -0.0001 1.003 (0.999–1.006) 0.098
Periop MI 5.78 (3.97–8.43) -0.0001 3.87 (2.43–6.18) -0.0001
Re-exploration 5.78 (4.27–7.83) -0.0001 2.55 (1.63–3.98) -0.0001
IABP 14.68 (10.51–20.50) -0.0001 4.76 (2.81–8.05) -0.0001
Hypertension 0.94 (0.73–1.21) 0.656
Off-pump 0.68 (0.41–1.17) 0.144
No graftsa 0.912 (0.817–1.018) 0.302
Entered as a continuous variable. HR, hazard ratio; RBC, red blood cells; FFP, fresh frozen plasma; COPD, chronic obstructive pulmonary disease; Preop CrCl,a
preoperative creatinine clearance; EF, ejection fraction; Preop Hb, preoperative hemoglobin level; PVD, peripheral vascular disease; Redo, previous cardiac
surgery; ECC, extra-corporeal circulation; Periop MI, perioperative myocardial infarction; IABP, intra-aortic balloon pump support; CABG, coronary artery bypass
grafting.
Table 4
Predictors of late mortality )30 days post-CABG; univariate and multivariate Cox regression analyses
Risk factor Univariate analyses Multivariate analysis
late mortality late mortality
HR (95% CI) P-value HR P-value
RBC 1.162 (1.128–1.196) -0.0001 1.035 (0.994–1.007) 0.091
FFP 1.149 (1.076–1.227) -0.0001 1.008 (0.928–1.093) 0.856
Platelets 1.333 (1.125–1.732) 0.032 1.197 (0.932–1.537) 0.159
Agea 1.094 (1.085–1.103) -0.0001 1.064 (1.055–1.073) -0.0001
Male gender 0.83 (0.72–0.96) 0.013 1.54 (1.33–1.77) -0.0001
COPD 1.80 (1.54–2.10) -0.0001 1.70 (1.49–1.95) -0.0001
Diabetes 1.74 (1.52–2.00) -0.0001 1.50 (1.32–1.71) -0.0001
CrCl mlØmin-1a 0.975 (0.972–0.977) -0.0001 0.989 (0.986–0.993) -0.0001
EF-35% 2.59 (2.03–3.31) -0.0001 2.51 (2.03–3.09) -0.0001
Preop Hba 0.612 (0.573–0.655) -0.0001 0.864 (0.825–0.904) -0.0001
PVD 2.30 (1.97–2.69) -0.0001 1.54 (1.34–1.78) 0.0001
Redo 1.54 (1.25–1.90) -0.0001 1.16 (0.94–1.42) 0.148
Hypertension 1.22 (1.07–1.38) 0.002 1.07 (0.95–1.20) 0.256
Year of operation 0.961 (0.938–0.985) 0.002 0.966 (0.940–0.993) 0.012
No. of graftsa 1.084 (1.027–1.144) 0.003 0.991 (0.940–1.043) 0.721
Periop MI 1.81 (1.33–2.47) -0.0001 1.99 (1.54–2.58) -0.0001
Re-exploration 1.62 (1.29–2.04) -0.0001 1.52 (1.19–1.93) 0.001
IABP 1.95 (1.38–2.76) -0.0001 1.94 (1.46–2.59) -0.0001
Emergency 1.25 (0.93–1.67) 0.128
Off-pump 0.76 (0.58–1.00) 0.053
Entered as a continuous variable. HR, hazard ratio; RBC, red blood cells; FFP, fresh frozen plasma; COPD, chronic obstructive pulmonary disease; Preop CrCl,a
preoperative creatinine clearance; EF-35, ejection fraction -35%; Preop Hb, preoperative hemoglobin level; PVD, peripheral vascular disease; Redo, previous
cardiac surgery; Periop MI, perioperative myocardial infarction; IABP, intra-aortic balloon pump support; CABG, coronary artery bypass grafting.
In Figs. 1 and 2, the long-term and expected survival of
the patients receiving 0 or 1–2 RBC and patients receiving
3–5 or 6–10 RBC is shown. Fig. 3 shows the correlation
between the number of transfused RBC units and the
predicted mortality.
Log-rank test showed significant differences between all
patient groups. One, five and nine years survival rates are
shown in Table 5. Patients receiving 0 RBC had a better
than expected five and nine years survival. No difference
was found between the one, five and nine years survival
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Fig. 1. Kaplan–Meier survival curve stratified by units of transfused red blood
cells and the expected survival for patients receiving -3 RBC units.
Fig. 2. Kaplan–Meier survival curve stratified by units of transfused red blood
cells and the expected survival for patients receiving two RBC units.
Fig. 3. Correlation between the number of transfused RBC units and the
predicted mortality.
Table 5
One, five and ten years observed and expected survival
1 year 5 years 9 years P-value
0 RBC -0.0001
Observed 95.9"0.3 89.3"0.5 79.0"1.2
Expected 95.8"0.1 85.7"0.2 72.7"0.7
Patients at risk 5659 2565 274
1–2 RBC 0.363
Observed 93.4"0.5 83.3"0.9 70.8"1.8
Expected 94.7"0.1 82.5"0.2 67.6"0.5
Patients at risk 2045 1125 157
3–5 RBC -0.0001
Observed 85.8"1.2 75.1"1.8 61.2"2.8
Expected 94.4"0.1 81.3"0.2 64.5"0.4
Patients at risk 741 435 63
6–10 RBC -0.0001
Observed 77.2"2.4 66.6"2.9 54.7"4.3
Expected 94.2"0.1 80.3"0.2 62.5"0.4
Patients at risk 237 131 21
Nine years because of small numbers at ten years. Results as percentage
cumulative survival"S.E. at the time of the interval.
rates of patients receiving 1–2 RBC and their expected
survival rates, whereas one, five and nine years survival
rates of patients receiving )2 RBC were worse than
expected.
4. Discussion
This study revealed the number of transfused RBC to be
an independent predictor of early but not for late mortality
after CABG. Compared to expected survival, we noted that
in patients receiving three or more units of RBC survival
was decreased significantly, whereas receiving no RBC
improved patient survival.
Blood products are transfused to increase hemoglobin and
thereby improving tissue oxygenation and finally outcome
w1, 3, 5–8x. However, several studies suggest that transfu-
sion of blood products may be harmful by increasing the
risk of postoperative infection, myocardial or cerebrovas-
cular ischemia, renal failure, poorer functional recovery
and death w1–5, 7, 8x. Transfusion of blood products may
initiate a second inflammatory response by modification of
the patient’s systemic response and by directly introducing
bioactive substances into the circulation, apart from the
primary inflammatory response initiated by cardiopulmo-
nary bypass w2–4, 6, 8, 9x. Our study has shown that
patients who received G3 RBC units had a higher incidence
of postoperative complications. This can explain the higher
early mortality in these patients.
According to Koch and colleagues w2x, patients who
received blood products had a significantly reduced post-
operative functional recovery at six months. Kuduvalli et
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al. as well as Murphy et al. described a higher mortality
rate in the first 30 days after operation as well as through
the first postoperative year in patients who received peri-
operative blood transfusions w3, 6x. Engoren et al. found
transfusion to be a risk factor for long-term (up to five
years) mortality w7x. Koch et al. showed a significantly
reduced survival of transfused patients at six months, five
and ten years w4x. Our findings of reduced long-term surviv-
al in patients receiving peri-operative RBC transfusions are
in agreement with these investigations, though in our study
the number of RBC transfusions was not identified as
an independent predictor of late mortality. Therefore,
reduced long-term survival in patients receiving )2 units
of RBC might be explained by higher early mortality.
The incidence of re-exploration (in most cases for exces-
sive bleeding) is much higher in patients receiving more
RBC. We tried to compensate for this possible confounding
effect by entering re-exploration into the multivariate
model together with the number of RBC. The threshold of
the hemoglobin level for transfusion of RBC in our center
is 9 gydl unless postoperative ischemia is present. The
threshold increases to 11 gydl in case of ischemia. This
explains why the incidence of peri-operative myocardial
infarction (MI) is higher in patients receiving more RBC. In
the present study, peri-operative MI was an independent
predictor of early as well as late mortality. After adjust-
ment for excessive bleeding and postoperative ischemia,
the number of transfused RBC is still an independent
predictor of early mortality.
With regard to other baseline characteristics, the patient
groups also appeared to be widely different. Well-known
risk factors for early as well as late mortality such as older
age, COPD, diabetes, low CrCl, EF-35%, and others were
more frequently found in patients receiving more RBC
transfusions. These findings are in agreement with the
findings of previous reports w2, 4, 5, 7, 8, 10x. When
adjusted for these risk factors by multivariate analyses,
transfusion of RBC was an independent risk factor for early
mortality after CABG. In order to eliminate the confounding
effect of exceptional surgical problems we excluded
patients who received )10 units of RBC. Such a massive
transfusion was mostly caused by massive blood loss or
other special circumstances which certainly affect the
prognosis.
In our study, the number off-pump coronary artery bypass
(OPCAB) operations is relatively small (8.9%). Although
OPCAB was not identified as a significant factor for early
or late mortality, the number of patients having OPCAB was
significantly higher in patients receiving no transfusion than
in the other groups. This means that OPCAB can decrease
the need for RBC transfusions, which confirms the conclu-
sions of other investigators w11x.
We used the Dutch CBS database to calculate the survival
of the general population cohorts. This organisation keeps
track of mortality rates of the overall Dutch population.
Late survival is highly dependent on age. Because age is
significantly different between the patient groups we found
it necessary to match for age when comparing long-term
survival after CABG to the long-term survival of a matched
general population cohort.
Female gender is considered an independent risk factor
for early mortality after CABG w12–14x. In this study, we
could not confirm this finding. Multivariate analysis, how-
ever, designates male gender as risk factor for late mortal-
ity. Abramov et al. concluded the same after adjustment
for other risk factors w12x. Therefore, we decided to match
the general population cohorts for sex.
In patients who did not receive any blood products we
observed a better than expected survival. However, these
results must be interpreted with care. Before undergoing
CABG, patients are screened for severe underlying diseases.
If severe underlying disease is present, it is aggressively
treated or alternative treatment to CABG is considered,
thus, biasing the CABG group. Survival of patients who
received 1–2 units of blood products was not significantly
different from the expected survival rate.
In patients who received )2 units of blood products a
worse than expected survival was noted. When studying
the survival curves and life table, it is obvious that after
the early postoperative period the curves run parallel. This
finding confirms our observation that the number of trans-
fused RBC was not a predictor of late mortality. It might
be reassuring for patients to know that if they survive the
first postoperative period, their prognosis is not influenced
anymore by the blood transfusions they received.
5. Limitations
This is an observational retrospective investigation, in
which unknown variables could influence final results.
Furthermore, we did not study the effect of duration of
RBC storage. This issue has been recently addressed w15x.
The strengths of this investigation are the large prospec-
tively collected data set and the follow-up period of ten
years.
6. Conclusion
Peri-operative transfusion of RBC is an independent, dose-
dependent risk factor for early but not for late mortality
after CABG. Compared to expected survival, receiving no
RBC improves patient’s long-term survival, whereas receiv-
ing three or more units of RBC decreases patient survival
significantly. This is mainly caused by a higher mortality
within the first 30 postoperative days in these patients.
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